Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Is a deal/buyout in 2022 realistic?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Comment by Kswdeluxon Nov 21, 2022 5:36pm
134 Views
Post# 35116961

RE:RE:RE:RE:RE:Is a deal/buyout in 2022 realistic?

RE:RE:RE:RE:RE:Is a deal/buyout in 2022 realistic?

westcoast1000 wrote: KSW,

Thanks for the valuable summary.

"Cleaning and locking" the data will not take long because there are not very many subjects and so not many numbers are involved overall.

So that part will not take much time.

But I agree with your overall conclusion about time elapsing to Q2 2023 before a release of the information to us, at least. 


Thanks for that info on cleaning up and locking... that helps to understand timing there.

Of course these time frame statements from the Aug CC are based solely on the mBC side and Pfizer's timing, but IMHO this gets totally skewed by the GOBLET results and Roche's intentions.

Serious pressure now on both Pfizer's and Roche's sides.

As far as I am concerned, I am ready for something big to happen any day now, its just a may matter of waiting days ?, weeks ?, hopefully not to many months ?....IMHO max within 4 months.... but hoping for sooner.

I want a nice Christmas present...

Cheers!
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities